44 results on '"Komaki, R."'
Search Results
2. Respiratory-driven lung tumor motion is independent of tumor size, tumor location, and pulmonary function
3. Recursive partitioning analysis of 1999 radiation therapy oncology group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): Identification of five groups with different survival
4. High-dose-rate endobronchial brachytherapy effectively palliates symptoms due to airway tumors: The 10-year M. D. Anderson Cancer Center experience
5. Outcome predictors for 143 patients with superior sulcus tumors treated by multidisciplinary approach at the University of Texas M. D. Anderson Cancer Center
6. Effectiveness of accelerated radiotherapy for patients with inoperable non-small cell lung cancer (NSCLC) and borderline prognostic factors without distant metastasis: a retrospective review - An interim report
7. Is prolonged survival possible for patients with supraclavicular node metastases in non-small cell lung cancer treated with chemoradiotherapy?: analysis of the radiation therapy oncology group experience - Mature results of Southwest Oncology Group phase II study 8805
8. Addition of Chemotherapy to Radiation Therapy Alters Failure Patterns by Cell Type Within Non-Small Cell Carcinoma of Lung (NSCCL): Analysis of Radiation Therapy Oncology Group (RTOG) Trials
9. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies - Is it useful?
10. A Pilot Trial of Hyperfractionated Thoracic Radiation Therapy With Concurrent Cisplatin and Oral Etoposide for Locally Advanced Inoperable Non-Small-Cell Lung Cancer: A 5-year Follow-up Report
11. Response, Toxicity, Failure Patterns, and Survival in Five Radiation Therapy Oncology Group (RTOG) Trials of Sequential and/or Concurrent Chemotherapy and Radiotherapy for Locally Advanced Non-Small-Cell Carcinoma of the Lung
12. Failure Patterns by Prognostic Group Determined by Recursive Partitioning Analysis (RPA) of 1547 Patients on Four Radiation Therapy Oncology Group (RTOG) Studies in Inoperable Nonsmall-Cell Lung Cancer (NSCLC)
13. Prognostic Significance of DNA Contents in Stage I Adenocarcinoma of the Lung
14. Factors Influencing the Development of Lung Fibrosis after Chemoradiation for Small Cell Carcinoma of the Lung: Evidence for Inherent Interindividual Variation
15. Prognostic Biomarker Study in Pathologically Staged N1 Non-Small Cell Lung Cancer
16. Integration of Filgrastim into Chemoradiation for Limited Small Cell Lung Cancer: A Phase I Study
17. Induction Cisplatin/Vinblastine and Irradiation vs. Irradiation in Unresectable Squamous Cell Lung Cancer: Failure Patterns by Cell Type in RTOG 88-08/ECOG 4588
18. Randomized Study of Chemotherapy/Radiation Therapy Combinations for Favorable Patients With Locally Advanced Inoperable Nonsmall Cell Lung Cancer: Radiation Therapy Oncology Group (RTOG) 92-04
19. Prognostic Factors in the Treatment of Node-Negative Nonsmall Cell Lung Carcinoma with Radiotherapy Alone
20. Apoptosis and Mitosis as Prognostic Factors in Pathologically Staged N1 Nonsmall Cell Lung Cancer
21. Neurological Sequelae in Long-Term Survivors of Small Cell Lung Cancer
22. The Use of Radiochromic Film to Measure Dose Distributions Resulting from High Dose Rate ^1^9^2Iridium Single Catheter Treatments
23. Phase II study of postoperative adjuvant therapy in patients with completely resected stage II and IIIA non-small cell lung cancer (RTOG 97-05)
24. Impairment of neurocognitive function in brain metastases patients: baseline results from the phase III trial with motexafin gadolinium
25. Preliminary results of a radiation therapy oncology group trial (RTOG 9311), a dose escalation study using 3d conformal radiation therapy in patients with inoperable nonsmall cell lung cancer
26. Do elderly patients (pts) with locally advanced non-small cell lung cancer (NSCLC) benefit from combined modality therapy? a secondary analysis of RTOG 94-10
27. Ki-67, p53 and bcl-2 expression as prognostic indicators for patients with resectable brain metastasis from non-small cell lung cancer
28. Age dramatically impacts on the quality-adjusted time without symptoms or toxicity (Q-Twist) in locally advanced non-small cell lung cancer (LA-NSCLC)-a radiation therapy oncology group (RTOG) analysis
29. The American Brachytherapy Society recommendations for brachytherapy of carcinoma of the lung
30. Most troublesome quality of life concerns in patients with brain metastases: baseline results from the phase III trial with motexafin gadolinium
31. The effects of radiation therapy, chemotherapy and the radioprotector amifostine on the diffusion capacity of patients with non-small cell lung cancer (NSCLC)
32. Long-term follow-up of RTOG 88-05: twice-daily external irradiation with brachytherapy for carcinoma of the cervix
33. One year follow-up reveals no difference in quality of life between high dose and conventional dose radiation: a quality of life assessment of RTOG 94-05
34. Randomized phase III study of amifostine in patients treated with chemoradiation for inoperable stage II-III non-small cell lung cancer (NSCLC)
35. Atypical bronchial carcinoid tumors have a high incidence of loco-regional failure
36. Concurrent chemoradiation for locally advanced NSCLC in the RTOG experience: effect of overall treatment time
37. Adjuvant IMRT for malignant mesothelioma
38. Sequential vs. concurrent chemotherapy and radiation therapy for inoperable non-small cell lung cancer (NSCLC): analysis of failures in a phase III study (RTOG> 9410)
39. Lymphocyte mutagen sensitivity correlates significantly with gender, histology, and radiation toxicity in lung cancer patients
40. Evaluation of Cognitive Function in Patients with Limited Small Cell Lung Cancer Prior to and Shortly Following Prophylactic Cranial Irradiation
41. Long-term Results of Treatment of Cervical Carcinoma in the United States in 1973, 1978, and 1983: Patterns of Care Study (PCS)
42. Interdigitating Versus Concurrent Chemotherapy and Radiotherapy for Limited Small Cell Lung Cancer
43. Modality sequence and prophylactic cranial irradiation (PCI) are most significant in recursive partitioning analysis (RPA) of patients with limited small cell lung cancer (SCLC) treated with combined modality therapy
44. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): A quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemo-radiation studies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.